Ignite Creation Date:
2024-05-06 @ 7:32 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06042049
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-22
First Post:
2023-07-13
Brief Title:
A Study to Assess Safety Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-09-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-04-10
Completion Date Type:
ESTIMATED
First Submit Date:
2023-07-13
First Submit QC Date:
September 11 2023
Study First Post Date:
2023-09-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-30
Last Update Post Date:
2024-05-22
Last Update Post Date Type:
ACTUAL